Trial reportCancer communications (London, England)2026
Rezivertinib in
Abstract readClinical Trial, Phase IIIRandomized Controlled TrialMulticenter Study
In one paragraph
Trial report in Cancer communications (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Sheng YangDepartment of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.
Yanqiu ZhaoRespiratory Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.
Meili SunDepartment of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P. R. China.
Minghong BiDepartment of Medical Oncology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, P. R. China.
Bo ZhuDepartment of Oncology, Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing, P. R. China.
Zhaohong ChenDepartment of Oncology, People's Hospital of Deyang City, Deyang, Sichuan, P. R. China.
Huiqing YuDepartment of Geriatric Oncology, Chongqing University Cancer Hospital, Chongqing, P. R. China.
Liangming ZhangDepartment of Medical Oncology, Yantai Yuhuangding Hospital, Yantai, Shandong, P. R. China.
Lin WuDepartment of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China.
Rui ZhouDepartment of Respiratory and Critical Care Medicine, The Second Xiangya Hospital of Central South University, Changsha, Hunan, P. R. China.
Wenxiu YaoDepartment of Medical Oncology, Sichuan Cancer Hospital/Cancer Hospital Affiliated to University of Electronic Science and Technology of China, Chengdu, Sichuan, P. R. China.
Xingya LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China.
Zhigang HanFirst Department of Medicine, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, P. R. China.
Ke WangDepartment of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
Lijun WangCancer Center, The Second Affiliated Hospital of Xingtai Medical College, Xingtai, Hebei, P. R. China.
Meiling WenDepartment of Medical Oncology, The First Affiliated Hospital of University of South China, Hengyang, Hunan, P. R. China.
Yanzhen GuoDepartment of Medical Oncology, The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, P. R. China.
Yingcheng LinDepartment of Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, P. R. China.
Shenghua SunDepartment of Pulmonary and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, P. R. China.
Shuliang GuoDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P. R. China.
Tienan YiDepartment of Medical Oncology, Xiangyang Central Hospital, Xiangyang, Hunan, P. R. China.
Wenhua ZhaoDepartment of Internal Medicine for Lung Cancer, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, P. R. China.
Zhuang YuDepartment of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P. R. China.
Jianwen QinDepartment of Respiratory and Critical Medicine, Chest Hospital, Tianjin University, Tianjin, P. R. China.
Yueyin PanDepartment of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, P. R. China.
Zhiyong HeDepartment of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, National Health Commission (NHC) Key Laboratory of Cancer Metabolism, Fuzhou, Fujian, P. R. China.
Feng YeDepartment of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, P. R. China.
Huaqiu ShiDepartment of Medical Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, P. R. China.
Jian FangDepartment of Thoracic Oncology, Beijing Cancer Hospital, Beijing, P. R. China.
Rui MaDepartment of Thoracic Oncology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.
Hong LuDepartment of Oncology, Huaihe Hospital of Henan University, Kaifeng, Henan, P. R. China.
Hua ZhangDepartment of Medical Oncology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, P. R. China.
Jianhua ShiDepartment of Medical Oncology, Linyi Cancer Hospital, Linyi, Shandong, P. R. China.
Jinghua GaoDepartment of Medical Oncology, Cangzhou Central Hospital, Cangzhou, Hebei, P. R. China.
Jiuwei CuiOncology Center, Oncology Department, First Hospital of Jilin University, Changchun, Jilin, P. R. China.
Manxiang LiDepartment of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, P. R. China.
Shanyong YiDepartment of Medical Oncology, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, P. R. China.
Shundong CangDepartment of Oncology, Henan Provincial People's Hospital, Zhengzhou, Henan, P. R. China.
Yongqian ShuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital), Nanjing, Jiangsu, P. R. China.
Don ZhangDepartment of Drug Discovery, Beta Pharma Inc., Princeton, NJ, USA.
Jirong PengDepartment of Drug Discovery, Beta Pharma Inc., Princeton, NJ, USA.
Feng GaoDepartment of Clinical Development, Beta Pharma (Shanghai) Co., Ltd., Shanghai, P. R. China.
Tingting WangDepartment of Clinical Development, Beta Pharma (Shanghai) Co., Ltd., Shanghai, P. R. China.
Anqi ZhouDepartment of Clinical Development, Beta Pharma (Shanghai) Co., Ltd., Shanghai, P. R. China.
Yuankai ShiDepartment of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.ORCID https://orcid.org/0000-0002-8685-6744
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, Non-Small-Cell LungCentral Nervous System NeoplasmsLung NeoplasmsProtein Kinase InhibitorsAdultAgedDouble-Blind MethodErbB ReceptorsFemaleGefitinibHumansIndolesMagnetic Resonance ImagingMaleMiddle AgedMutationEGFR protein, humanErbB ReceptorsGefitinibIndolesProtein Kinase InhibitorsPyrimidinesrezivertinib
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.